Matrix metalloproteinases in cancer: Prognostic markers and targets for therapy (Review)

International Journal of Oncology

Volumn 12, Issue 6, 1998, Pages 1343-1348

  Duffy, M J ^a   McCarthy, K ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cancer progression; Invasion; Matrix metalloproteinases; Metastasis; Prognosis; Tissue inhibitor of metalloproteinases

Indexed keywords

BATIMASTAT; COLLAGENASE; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBRONECTIN; GELATINASE; GELATINASE A; GELATINASE B; LAMININ; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PROTEOGLYCAN; STROMELYSIN; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; CANCER; CANCER GROWTH; CANCER INVASION; DISEASE ASSOCIATION; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MYALGIA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

EID: 0031842208     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.6.1343     Document Type: Article

References (49)

1. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 5: 2145-2154, 1991.
2. Pei D and Weiss S: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 375: 244-247, 1995.
3. Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinase in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
4. Duffy MJ: Role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145-155, 1992.
5. Levi E, Fridman R, Miao H-Q, Ma Y-S, Yayon A and Vlodavsky I: Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 93: 7069-7074, 1996.
6. Rei D, Majmudar G and Weiss SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 269: 25849-25855, 1994.
7. Murphy G, Segain JP, O'Shea M, Cockett C, Joannou C, Lefebvre O, Chambon P and Basset P: The 28 kD N-terminal domain of mouse stromelysin-3 has the general properties of a weak stromelysin-like metalloproteinase. J Biol Chem 268: 15435-15441, 1993.
8. Rio M-C, Lefebvre O, Santavicca M, Noel A, Chenard M-P and Anglard P: Stromelysin-3 in the biology of the normal and neoplastic mammary gland. J Mam Gland Biol Neopl 1: 231-240, 1996.
9. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65, 1994.
10. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M and Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 272: 2446-2451, 1997.
11. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E and Iwata K: Growth promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells, a possible new growth factor in serum. FEBS Lett 298: 29-32, 1992.
12. Nemeth JA and Goolsby CL: TIMP-2, a growth stimulating protein from SV-40 transformed human fibroblasts. Exp Cell Res 207: 376-382, 1993.
13. Garbisa S, Pozzatti R, Muschel R, Saffiotti U, Ballin M and Goldfarb R: Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not with c-Ha-ras plus Ad2-Ela. Cancer Res 47: 1523-1528, 1987.
14. Schultz RM, Silberman S, Persky B, Bajkowski AS and Carmichel DF: Inhibition of recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonisation by murine B16-F10 melanoma cells. Cancer Res 48: 5539-5545, 1988.
15. Alvarez OA, Carmichael DF and De Clerck YA: Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 82: 589-595, 1990.
16. Montgomery AMP, Mueller BM, Reisfeld RA, Taylor SM and De Clerck YA: Effect of tissue inhibitor of the matrix metalloproteinase-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 54: 5467-5473, 1994.
17. Khokha R and Denhardt DT: Matrix-metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumorigenesis and tissue invasion. Invasion Metastasis 9: 391-405, 1989.
18. Talbot DC and Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528-2533, 1996.
19. Hua J and Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56: 5279-5284, 1996.
20. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, et al: Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 63: 568-575, 1995.
21. Bernhard EJ, Gruber SB and Muschel R: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91: 4293-4297, 1994.
22. Duffy MJ: The biochemistry of metastasis. Adv Clin Chem 32: 136-166, 1996.
23. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF and Groom AC: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 54: 4791-4797, 1994.
24. Witty JP, McDonnell S, Newell K, Cannon P, Navre M, Tressler R and Matrisian LM: Modulation of matrilysin levels in colon carcinoma cell lines affect tumorigenicity in vivo. Cancer Res 54: 4805-4812, 1994.
25. Wilson CL, Heppner K, Labosky PA, Hogan BLM and Matrisian L: Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402-1407, 1997.
26. Duffy MJ: Do proteases play a role in cancer invasion and metastasis? Eur J Cancer Clin Oncol 23: 583-589, 1987.
27. Duffy MJ, O'Grady P, Devaney P, O'Siorain L, Fennelly JJ and Lijnen HJ: Urokinase plasminogen activator, a marker for aggressive breast cancers. Preliminary report. Cancer 62: 531-533, 1988.
28. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
29. Daidone MG, Silvestrini R, D'Errico A, Di Fronza G, Benini E, Mancini AM, et al: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529-532, 1991.
30. Visscher DW, Hoyhtya M, Ottosem SK, Liang C-M, Sarkar FH, Crissman JD and Fridman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 59: 339-344, 1994.
31. Remade A, Noel A, Duggan C, McDermott E, O'Higgins N, Foidart JM and Duffy MJ: Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. Br J Cancer 77: 926-931, 1998.
32. Engel G, Heselmeyer K, Auer G, Backdahl M, Eriksson E and Linder S: Correlation between stromelysin-3 mRNA levels and outcome of human breast cancer. Int J Cancer 58: 830-835, 1994.
33. Chenard M-P, O'Siorain L, Shering S, Rouyer N, Lutz Y, Wolf C, et al: High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int J Cancer 69: 448-451, 1996.
34. Sier CFM, Kubben F, Ganesh S, Heerding MH, Griffioen G, Hanemaaijer R, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996.
35. Mori M, Mimori K, Shiraishi T, Fujie T, Baba K, Kusumoto H, et al: Analysis of MT-MMP-1 and MMP-2 expression in human gastric cancers. Int J Cancer 74: 316-321, 1997.
36. Zeng ZS, Huang Y, Cohen AM and Guillem JG: Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133-3140, 1996.
37. Murray GI, Duncan ME, O'Neill P, Melvin WT and Fothergill JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462, 1996.
38. Gohi K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S and Nakajima M: Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 78: 2379-2387, 1996.
39. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM and Fodstad O: High levels of mRNA for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of metastases. Clin Cancer Res 3: 1623-1628, 1997.
40. Fong KM, Kida Y, Zimmerman PV and Smith PJ: TIMP-1 and adverse prognosis in small cell lung cancer. Clin Cancer Res 2: 1369-1372, 1996.
41. Grignon DJ, Sakr W, Toth M, Ravery V, Angulo J, Shamsa F. et al: High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 56: 1654-1659, 1996.
42. Andreasen P, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
43. Beckett RP: Recent advances in the field of metalloproteinase inhibitors. Exp Opin Ther Patents 6: 1305-1315, 1996.
44. Brown PD and Giavazzi R:'Matrix metalloproteinases inhibition: a review of anti-tumor activity. Ann Oncol 6: 967-974, 1995.
45. De Clerck YA and Imren S: Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 30A: 2170-2180, 1994.
46. Wojtowicz-Praga SM, Dickson RB and Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61-75, 1997.
47. Gore M, A'Hern R, Stankiewicz M and Slevin M: Tumor marker levels during marimastat therapy. Lancet 348: 263-264, 1996.
48. Rasmussen HS and McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75: 69-75, 1997.
49. Opdenakker G, Paemen L, Norga K and Masure S: Proteinase inhibition in invasive cancer therapy: four control levels of matrix degradation. Int J Cancer 70: 628-630, 1997.